Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks

• Home
• Organization
  • Governance and By-Laws
  • Executive Committee
  • Oversight Committee
  • Consortia and Collaborations
  • Working Groups
• Meetings
  • ADEPT
    March 2011
  • ACTION-1
    June 2011
  • ACTTION-2
    October 2012
  • ACTTION-3
    June 2014
• Resources
  • Pain Database Standards
  • RReACT Database
  • RReADS Database
  • RReMIT Database
• Publications
• Partners
• IMMPACT
• Contact Us

November 10, 2015: ACTTION Presentation at National Academy of Medicine Forum on Neuroscience and Nervous System Disorders

The National Academy of Medicine Forum on Neuroscience and Nervous System Disorders held a session to explore the application of the Accelerating Medicines Partnership (AMP) to pain. The AMP is a public-private partnership between NIH, FDA, biopharmaceutical companies, and non-profit organizations to jointly identify and validate biological targets for the development of new diagnostics and therapeutics. Currently, AMP is supporting projects on Alzheimer's disease, type 2 diabetes, rheumatoid arthritis, and lupus. The Forum was interested in learning about the ACTTION public-private partnership and Kushang Patel, PhD, ACTTION Assistant Director, presented an overview of ACTTION’s mission, accomplishments, and ongoing activities. The Forum also received briefings from academic and industry investigators on current research on brain imaging and genetic and proteomic biomarkers of pain. Participants will continue to consider pain as a candidate condition for the AMP.